JP2014520764A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014520764A5 JP2014520764A5 JP2014517444A JP2014517444A JP2014520764A5 JP 2014520764 A5 JP2014520764 A5 JP 2014520764A5 JP 2014517444 A JP2014517444 A JP 2014517444A JP 2014517444 A JP2014517444 A JP 2014517444A JP 2014520764 A5 JP2014520764 A5 JP 2014520764A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- interferon
- disease
- pharmaceutical composition
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 102000003951 Erythropoietin Human genes 0.000 claims 9
- 108090000394 Erythropoietin Proteins 0.000 claims 9
- 229940105423 erythropoietin Drugs 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 9
- NNMALANKTSRILL-ZUTFDUMMSA-N 3-[(2z,5z)-2-[[3-(2-carboxyethyl)-5-[(z)-[(3z,4r)-3-ethylidene-4-methyl-5-oxopyrrolidin-2-ylidene]methyl]-4-methyl-1h-pyrrol-2-yl]methylidene]-5-[(4-ethyl-3-methyl-5-oxopyrrol-2-yl)methylidene]-4-methylpyrrol-3-yl]propanoic acid Chemical group O=C1C(CC)=C(C)C(\C=C/2C(=C(CCC(O)=O)C(=C/C3=C(C(C)=C(\C=C/4\C(\[C@@H](C)C(=O)N\4)=C/C)N3)CCC(O)=O)/N\2)C)=N1 NNMALANKTSRILL-ZUTFDUMMSA-N 0.000 claims 6
- 102000000588 Interleukin-2 Human genes 0.000 claims 5
- 108010002350 Interleukin-2 Proteins 0.000 claims 5
- INPDFIMLLXXDOQ-UHFFFAOYSA-N Phycocyanobilin Natural products CCC1=C(C)C(=CC2=NC(=C/c3[nH]c(C=C/4C(C(C(N4)=O)C)=CC)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O INPDFIMLLXXDOQ-UHFFFAOYSA-N 0.000 claims 5
- 208000015114 central nervous system disease Diseases 0.000 claims 5
- 208000028867 ischemia Diseases 0.000 claims 5
- 108010072011 phycocyanobilin Proteins 0.000 claims 5
- 102000006992 Interferon-alpha Human genes 0.000 claims 4
- 108010047761 Interferon-alpha Proteins 0.000 claims 4
- 102000003996 Interferon-beta Human genes 0.000 claims 4
- 108090000467 Interferon-beta Proteins 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229960001388 interferon-beta Drugs 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000030090 Acute Disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000017667 Chronic Disease Diseases 0.000 claims 2
- 101000997570 Homo sapiens Appetite-regulating hormone Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 102000002227 Interferon Type I Human genes 0.000 claims 2
- 108010014726 Interferon Type I Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000000626 neurodegenerative effect Effects 0.000 claims 2
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 claims 1
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 201000004559 cerebral degeneration Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2011000146A CU23963B1 (es) | 2011-07-01 | 2011-07-01 | Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas |
| CU2011/0146 | 2011-07-01 | ||
| PCT/CU2012/000003 WO2013004203A1 (es) | 2011-07-01 | 2012-06-29 | Compuestos y combinaciones farmacéuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014520764A JP2014520764A (ja) | 2014-08-25 |
| JP2014520764A5 true JP2014520764A5 (enExample) | 2015-08-20 |
| JP6023803B2 JP6023803B2 (ja) | 2016-11-09 |
Family
ID=46614264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517444A Active JP6023803B2 (ja) | 2011-07-01 | 2012-06-29 | 神経変性及び虚血性脳疾患を処置するための化合物及び薬学的組合せ |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9518085B2 (enExample) |
| EP (1) | EP2733149B9 (enExample) |
| JP (1) | JP6023803B2 (enExample) |
| KR (1) | KR101987978B1 (enExample) |
| CN (1) | CN103649106B (enExample) |
| AR (1) | AR087034A1 (enExample) |
| AU (1) | AU2012280776B2 (enExample) |
| BR (1) | BR112013033970B1 (enExample) |
| CA (1) | CA2838496C (enExample) |
| CU (1) | CU23963B1 (enExample) |
| DK (1) | DK2733149T3 (enExample) |
| ES (1) | ES2601887T3 (enExample) |
| IN (1) | IN2014CN00510A (enExample) |
| MX (1) | MX345534B (enExample) |
| RU (1) | RU2569302C2 (enExample) |
| SI (1) | SI2733149T1 (enExample) |
| WO (1) | WO2013004203A1 (enExample) |
| ZA (1) | ZA201309554B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014206899A1 (en) * | 2013-06-25 | 2014-12-31 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Boosting treg cells for treating alzheimer disease and related disorders |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| RU2613765C1 (ru) * | 2016-01-26 | 2017-03-21 | Федеральное государственное автономное образовательное учреждение высшего образования "Северо-Восточный федеральный университет им. М.К.Аммосова" | Способ лечения спиноцеребеллярной атаксии |
| CN108752445B (zh) * | 2018-06-20 | 2021-04-30 | 广东药科大学 | 一种螺旋藻蛋白的制备工艺及其神经保护用途 |
| KR102152407B1 (ko) * | 2019-02-26 | 2020-09-07 | (주)나우코스 | 스피루리나에서 유래한 파이코시아노블린 및 이의 유도체를 유효성분으로 포함하는 화장료 조성물 |
| KR20210091664A (ko) | 2020-01-14 | 2021-07-22 | 경북대학교 산학협력단 | 중간엽 줄기세포 유래 단백질을 포함하는 소뇌성운동실조증의 치료 예후를 예측하기 위한 바이오마커, 및 이를 이용한 소뇌성운동실조증의 치료용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5709855A (en) | 1995-09-22 | 1998-01-20 | Bockow; Barry I. | Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain |
| US20040110938A1 (en) * | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
| US7025965B1 (en) * | 2003-02-12 | 2006-04-11 | Pharma Chemie, Inc. | Method of use and dosage composition of bluegreen algae extract for inflammation in animals |
| EP1608400B1 (en) * | 2003-03-28 | 2010-06-23 | Faron Pharmaceuticals OY | Elevation of adenosine level by cytokine-induced expression of cd73 |
| CU23581A1 (es) * | 2005-10-28 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer |
| SI2046354T1 (sl) * | 2006-06-27 | 2011-11-30 | Nutratec S R L | Pripravek iz aphanizomenon flos aquae izvlečki in očiščene sestavine le-te za zdravljenje nevroloških nevrodegenerativnih in razpoloženjskih motenj |
| CN101677992A (zh) * | 2006-11-13 | 2010-03-24 | M·F·麦卡蒂 | 抑制nadph氧化酶活性的组合物 |
-
2011
- 2011-07-01 CU CU2011000146A patent/CU23963B1/es unknown
-
2012
- 2012-06-29 KR KR1020147002552A patent/KR101987978B1/ko active Active
- 2012-06-29 JP JP2014517444A patent/JP6023803B2/ja active Active
- 2012-06-29 BR BR112013033970-5A patent/BR112013033970B1/pt active IP Right Grant
- 2012-06-29 CA CA2838496A patent/CA2838496C/en active Active
- 2012-06-29 DK DK12743356.3T patent/DK2733149T3/en active
- 2012-06-29 IN IN510CHN2014 patent/IN2014CN00510A/en unknown
- 2012-06-29 ES ES12743356.3T patent/ES2601887T3/es active Active
- 2012-06-29 AU AU2012280776A patent/AU2012280776B2/en not_active Ceased
- 2012-06-29 MX MX2013015206A patent/MX345534B/es active IP Right Grant
- 2012-06-29 WO PCT/CU2012/000003 patent/WO2013004203A1/es not_active Ceased
- 2012-06-29 US US14/127,369 patent/US9518085B2/en active Active
- 2012-06-29 CN CN201280032375.5A patent/CN103649106B/zh active Active
- 2012-06-29 EP EP12743356.3A patent/EP2733149B9/en active Active
- 2012-06-29 SI SI201230756A patent/SI2733149T1/sl unknown
- 2012-06-29 RU RU2014103246/04A patent/RU2569302C2/ru active
- 2012-07-02 AR ARP120102397A patent/AR087034A1/es unknown
-
2013
- 2013-12-18 ZA ZA2013/09554A patent/ZA201309554B/en unknown
-
2016
- 2016-11-10 US US15/348,451 patent/US20170119733A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014520764A5 (enExample) | ||
| RU2014103246A (ru) | Соединения и фармацевтические комбинации для лечения нейродегенеративных и ишемических болезней мозга | |
| KR102375262B9 (en) | GLP-1 Pharmaceutical composition comprising sustained release-microsphere comprising GLP-1 Analogue or pharmaceutically acceptable salt thereof | |
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| JP2012115277A5 (enExample) | ||
| JP2018505146A5 (enExample) | ||
| JP2015513544A5 (enExample) | ||
| WO2012012600A3 (en) | Peptide compounds for regulating the complement system | |
| JP2016517421A5 (enExample) | ||
| RU2010111114A (ru) | Нейропротективное действие с применением nap-подобных и sal-подобных пептидных миметиков | |
| JP2014510101A5 (enExample) | ||
| JP2019513752A5 (enExample) | ||
| FI3712264T3 (fi) | Kystationiini-beta-syntaasientsyymi homokystinurian hoitoon | |
| IL276158B2 (en) | Methods and preparations for the treatment of angiogenic disorders using anti-VEGF factors | |
| JP2015502389A5 (enExample) | ||
| JP2017501999A5 (enExample) | ||
| JP2010509345A5 (enExample) | ||
| WO2008057609A4 (en) | Methods of treating neuronal disorders using mntf peptides and analogs thereof | |
| JP2013535965A5 (enExample) | ||
| JP2015514771A5 (enExample) | ||
| EP4219534A3 (en) | Methods for treatment of and prophylaxis against inflammatory disorders | |
| KR102084341B1 (ko) | 짧은 합성 펩티드 및 그의 용도 | |
| HRP20250746T1 (hr) | Peptidni spojevi i njihova terapijska upotreba | |
| JP2015524808A5 (enExample) | ||
| JP2019516675A5 (enExample) |